Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

04:12 EDT 29th May 2015 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 16,000+

Extremely Relevant

ASCO GI: Combining newer, more intensive first-line chemo with bevacizumab improves long-term outcome in advanced colorectal cancer

Updated results from TRIBE, an Italian phase III study of patients with metastatic colorectal cancer, indicate that FOLFOXIRI chemotherapy in combination with bevacizumab is superior to the standard FOLFIRI chemotherapy with bevacizumab. Compared to...

New First-line Option for Advanced Colorectal Cancer

In patients with advanced colorectal cancer, the rate of 5-year overall survival was twice as high with FOLFOXIRI plus bevacizumab as with FOLFIRI plus bevacizumab. Medscape Medical News

New Agent Active in Refractory Metastatic Colorectal Cancer

Treatment with TAS-102 improved survival in heavily pretreated patients with metastatic colorectal cancer, including those refractory to fluorouracil. Medscape Medical News

FDA approves ramucirumab for metastatic colorectal cancer

The US Food and Drug Administration has approved ramucirumab (Cyramza) for use in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first line bevacizumab-, oxaliplatin- ...

Lilly's Cryamza Receives Fourth FDA Approval

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration (FDA) approval for Cryamza (ramucirumab). Cryamza (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with Folfiri (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior ther...

Cornerstone begins Phase I trial of CPI-613 to treat metastatic colorectal cancer

Cornerstone Pharmaceuticals has started a Phase I clinical trial of its lead Altered Energy Metabolism Directed (AEMD) drug candidate, CPI-613, in combination with fluorouracil (5-FU), to treat with non-resectable metastatic colorectal cancer who hav…

March Is National Colorectal Cancer Awareness Month

OMNI Health Media (OMNI) announces the launch of colorectal cancer programs for national colorectal cancer awareness month. As the month of March brings colorectal cancer into focus, it’s time to increase public understanding of the disease, includ...

Erbitux Appears Superior to Avastin for Initial Colorectal Cancer Therapy

Results of the phase III “Fire” trials were recently published in the medical journal The Lancet Oncology. The results of the study suggest that patients with metastatic colorectal cancer treated with Erbitux (cetuximab) combined with standard fi...

Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies

The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-lin...

Relevant

Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer

New indication for bevacizumab in cervical cancer

Bevacizumab, a monoclonal antibody most commonly used to treat bowel, breast and kidney cancer, may soon receive marketing authorisation for cervical cancer. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)...

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

How aspirin fights colorectal cancer

Taking aspirin reduces a person's risk of colorectal cancer, but the molecular mechanisms involved have remained unknown until a recent discovery. discovered that aspirin might exert its chemopreventive activity against colorectal cancer, at least pa...

Colorectal cancer: Back to the stroma—the real villain in colorectal cancer?

The cells responsible for particular gene signatures in large-scale microarray studies of colorectal cancer have now been revealed. In doing so, the gene signature associated with poor prognosis is shown to be predominantly of stromal origin.

Helpful predictability in colorectal cancer

    SOURCE Feb 20, 2015 Two recent studies in Genome Biology measuring the mutational difference between the primary and metastatic colorectal cancer confirm high concordance of mutations on the genome-wide scale. Colorectal cancer progression is linear. The alternative model of progression that are cancer types follow is branched evolution, […]

TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com

Dallas, TX (PRWEB) December 26, 2014 The report “TS-1 (Colorectal Cancer) – Forecast and Market Analysis to 2023” focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorect...

Vitamin D Protects Against Colorectal Cancer

A new study by Dana-Farber Cancer Institute investigators demonstrates that vitamin D can protect some people with colorectal cancer by perking up the immune system’s vigilance against tumor cells.R

AAPS PharmSciTech: Topical Delivery of 5-Fluorouracil from Pheroid™ Formulations and the In Vitro Efficacy Against Human Melanoma

Type: Original PaperDrug delivery vehicles can influence the topical delivery and the efficacy of an active pharmaceutical ingredient (API). In this study, the influence of Pheroid™ technology, which is a unique colloidal drug delivery system, on t...

Bio-marker set forms the basis for new blood test to detect colorectal cancer

SOURCE MARCH 30, 2015 Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Researchers from VIB and KU […]

Biomarker set forms the basis for new blood test to detect colorectal cancer

Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Researchers from VIB and KU...

Biothera Immunotherapy Combination Results in Tumor Reduction During Maintenance Phase of Non-Small Cell Lung Cancer Study

The combination of the investigational cancer immunotherapy Imprime PGG and the monoclonal antibody bevacizumab achieved additional meaningful reductions in tumor burden during the maintenance phase of Biothera’s recent phase 2 clinical trial in non-small cell lung cancer (NSCLC). The new data will be released today at the European Lung Cancer Conference. ...

One-two punch of drugs better than either alone against colorectal cancer

(University of Colorado Denver) Experimental anti-cancer agents PF-04691502 and PD-0325901 excel in lab tests against colorectal cancer models and enter phase 1 trial.

U of Colorado researchers find that a one-two punch of drugs is better than either alone against colorectal cancer in mice

Experimental anti-cancer agents PF-04691502 and PD-0325901 excel in lab tests against colorectal cancer models and enter phase 1 trial.

March for colorectal cancer awareness

A 75-year-old woman with progressive constipation. An 82-year-old man with unexplained anemia. A 39-year-old mother of two with intermittent blood in her stool. These are three of my patients. And sadly, they are three of nearly 150,000 Americans diagnosed with colorectal cancer every year. March is National Colorectal Cancer Awareness Month for good reason. In […]

Reaching '80 percent by 2018' would prevent more than 20,000 colorectal cancer deaths per year

(American Cancer Society) Increasing colorectal cancer screening rates to 80 percent by 2018 would prevent an additional 21,000 colorectal cancer deaths per year by 2030, according to a new study.


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks